Pre-TAVR and post-TAVR clinical characteristics
| All patients (n=32) | Control (n=11) | LBBB (n=11) | P value compared with control | RVP (n=10) | P value compared with control | |
| Baseline clinical characteristics | ||||||
| Age, years | 85.8±8.9 | 85.7±11.3 | 85.7±4.3 | 0.5 | 86.0±11.0 | 0.5 |
| Sex, female (%) | 41 | 73 | 36 | 0.05 | 10 | 0.001 |
| BMI (kg/m2) | 24.9±3.1 | 24.7±2.5 | 25.4±3.4 | 0.3 | 24.6±3.7 | 0.4 |
| NYHA class | 2.8±0.5 | 2.8±0.4 | 2.8±0.8 | 0.4 | 2.8±0.4 | 0.4 |
| STS-PROM score (%) | 7.6±3.7 | 6.7±4.2 | 7.4±3.3 | 0.4 | 8.8±3.8 | 0.1 |
| Mean five metre walk test (seconds) | 9.5±7.9 | 7.2±3.6 | 11.7±12.3 | 0.2 | 8.9±4.3 | 0.2 |
| Creatinine (mg/dL) | 1.3 | 1.2 | 1.1 | 0.4 | 1.6 | 0.08 |
| Atrial fibrillation (%) | 28 | 27 | 18 | 0.3 | 40 | 0.4 |
| Hypertension | 69 | 82 | 64 | 0.2 | 60 | 0.1 |
| Diabetes mellitus | 28 | 18 | 36 | 0.2 | 30 | 0.3 |
| Smoker within 1 year | 6 | 0 | 9 | 0.2 | 10 | 0.2 |
| CAD (%) | 66 | 36 | 91 | 0.003 | 70 | 0.07 |
| Prior MI (%) | 16 | 0 | 27 | 0.03 | 20 | 0.07 |
| Prior PCI (%) | 28 | 27 | 36 | 0.3 | 20 | 0.4 |
| Prior CABG (%) | 22 | 9 | 27 | 0.1 | 30 | 0.1 |
| Medications | ||||||
| Aspirin | 100 | 100 | 100 | 0.5 | 100 | 0.5 |
| ACE inhibitor | 38 | 36 | 27 | 0.3 | 50 | 0.3 |
| Beta blocker | 56 | 55 | 73 | 0.2 | 40 | 0.3 |
| Statin | 69 | 64 | 82 | 0.2 | 60 | 0.4 |
| 1-month post-TAVR clinical characteristics | ||||||
| Ventricular pacing frequency (%) | 97 (n=9) | |||||
BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; LBBB, left bundle branch block; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; RVP, right ventricular paced rhythm; STS-PROM, Society of Thoracic Surgeons-predicted risk of mortality; TAVR, transcatheter aortic valve replacement.